Home/ Stocks/ CUE

Cue Biopharma, Inc.

CUE XNAS

$0.25 -0.02 (-6.54%) ▼ 15-min delayed

Open

$0.26

High

$0.26

Low

$0.25

Volume

604.9K

Market Cap

$26.00M

About Cue Biopharma, Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 29 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$27.47M	$-26,602,000	$-0.28
FY 2025	$27.47M	$-26,602,000	$-0.28
Q3 2025	$2.15M	$-7,448,000	$-0.07
Q2 2025	$2.95M	$-8,482,000	$-0.09

Related Market News

No specific coverage for CUE yet. Check out our latest market news or earnings calendar.

Get CUE Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Cue Biopharma, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.